Picture loading failed.

Anti-IL23A therapeutic antibody (Pre-made Risankizumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Risankizumab, sold under the brand name Skyrizi, is a humanized monoclonal antibody targeting interleukin 23A (IL-23A). Risankizumab is part of a collaboration between Boehringer Ingelheim and AbbVie. Risankizumab has been approved in the European Union,[4] the United States, Canada, and Japan for treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.

Order information

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-486-1mg 1mg 3090
GMP-Bios-ab-486-10mg 10mg 21890
GMP-Bios-ab-486-100mg 100mg 148000
GMP-Bios-ab-486-xmg >100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Anti-IL23A therapeutic antibody (Pre-made Risankizumab biosimilar,Whole mAb)
INN Name Risankizumab
FormatWhole mAb
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2015
Year Recommended2016
CompaniesAbbVie;Boehringer Ingelheim
Conditions ApprovedErythrodermic psoriasis;Plaque psoriasis;Psoriatic arthritis;Pustular psoriasis
Conditions ActiveCrohn's disease;Ulcerative colitis;Atopic dermatitis
Conditions DiscontinuedPsoriasis;Ankylosing spondylitis;Asthma
Development Techna